What does this research mean for the field?

Finerenone reduces the urinary albumin-to-creatinine ratio in adults with type 1 diabetes and chronic kidney disease compared to placebo. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the effectiveness of finerenone in reducing urinary albumin levels in adults with type 1 diabetes and chronic kidney disease.

March 7, 2026New England Journal of Medicine

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

View Full Paper

Ask AI

Bookmark

To evaluate the effectiveness of finerenone in reducing urinary albumin levels in adults with type 1 diabetes and chronic kidney disease.
Clinical trial design
Comparison of finerenone with placebo
Measurement of urinary albumin-to-creatinine ratio
Finerenone led to a greater decrease in urinary albumin-to-creatinine ratio compared to placebo.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Clinical trial shows finerenone decreases urinary albumin-to-creatinine ratio in adults with type 1 diabetes, indicating potential kidney health benefits.

Cite This Study

Heerspink et al. (2026) studied this question.

synapsesocial.com/papers/69abc0925af8044f7a4e9367 https://doi.org/10.1056/nejmoa2512854

View Full Paper

Ask AI

Bookmark

Implication

Clinical trial shows finerenone decreases urinary albumin-to-creatinine ratio in adults with type 1 diabetes, indicating potential kidney health benefits.

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

Key Points

Discussion

Implication

Cite This Study

Finerenone in Type 1 Diabetes and Chronic Kidney Disease

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider